新辅助曲妥珠单抗-emtansine联合帕妥珠单抗治疗人表皮生长因子受体2阳性乳腺癌:III期KRISTINE研究的3年结局
KRISTINE研究对比新辅助T-DM1+P与TCH+P治疗HER2阳性II-III期乳腺癌,T-DM1+P病理完全缓解率较低(44.4% vs 55.7%,P=.016)但≥3级和严重不良事件较少。3年随访显示T-DM1+P的EFS事件风险更高(HR 2.61,95%CI 1.36-4.98),主要因术前局部区域进展事件更多(15例[6.7%] vs 0例),术后IDFS事件风险两组相似(HR 1.11,95%CI 0.52-2.40)。
要点
- T-DM1+P组病理完全缓解率44.4%低于TCH+P组55.7%(P=.016)。
- T-DM1+P组EFS事件风险更高(HR 2.61,95%CI 1.36-4.98),术前局部区域进展事件15例(6.7%)vs 0例。
- 术后IDFS事件风险两组相似(HR 1.11,95%CI 0.52-2.40),病理完全缓解与IDFS事件风险降低相关(HR 0.24,95%CI 0.09-0.60)。
核心结论
- 与TCH+P相比,T-DM1+P因术前局部区域进展事件导致EFS事件风险更高,术后IDFS事件风险相似,新辅助治疗期间≥3级不良事件更少,但辅助治疗期间导致治疗终止的不良事件更多。
研究设计与样本
- III期KRISTINE研究,将HER2阳性II-III期乳腺癌患者随机分配至新辅助T-DM1+P或TCH+P每3周共6周期,T-DM1+P组继续辅助T-DM1+P,TCH+P组接受辅助曲妥珠单抗联合帕妥珠单抗。
- 共444例患者随机分配(T-DM1+P组n=223;TCH+P组n=221),中位随访37个月。
主要发现
- T-DM1+P组EFS事件风险更高(HR 2.61,95%CI 1.36-4.98),术前局部区域进展事件T-DM1+P组15例(6.7%)vs TCH+P组0例。
- 术后IDFS事件风险两组相似(HR 1.11,95%CI 0.52-2.40)。
- 病理完全缓解与IDFS事件风险降低相关(HR 0.24,95%CI 0.09-0.60),与治疗组无关。
- 总体≥3级不良事件T-DM1+P组31.8% vs TCH+P组67.7%,T-DM1+P组更少。
- 辅助治疗期间≥3级不良事件T-DM1+P组24.5% vs TCH+P组9.9%,导致治疗终止的不良事件T-DM1+P组18.4% vs TCH+P组3.8%,T-DM1+P组更多。
关键数值与推荐
- 病理完全缓解率T-DM1+P组44.4% vs TCH+P组55.7%(P=.016)。
- EFS事件风险T-DM1+P组对比TCH+P组HR 2.61(95%CI 1.36-4.98)。
- IDFS事件风险T-DM1+P组对比TCH+P组HR 1.11(95%CI 0.52-2.40)。
- 病理完全缓解者IDFS事件风险HR 0.24(95%CI 0.09-0.60)。
- 新辅助治疗期间患者报告结局 favored T-DM1+P,辅助治疗期间与曲妥珠单抗联合帕妥珠单抗相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2-positive stage II to III breast cancer. T-DM1+P led to a lower pathologic complete response rate (44.4% v 55.7%; P = .016), but fewer grade 3 or greater and serious adverse events (AEs). Here, we present 3-year outcomes from KRISTINE. METHODS: Patients were randomly assigned to neoadjuvant T-DM1+P or TCH+P every 3 weeks for six cycles. Patients who received T-DM1+P continued adjuvant T-DM1+P, and patients who received TCH+P received adjuvant trastuzumab plus pertuzumab. Secondary end points included event-free survival (EFS), overall survival, patient-reported outcomes (measured from random assignment), and invasive disease-free survival (IDFS; measured from surgery). RESULTS: Of patients, 444 were randomly assigned (T-DM1+P, n = 223; TCH+P, n = 221). Median follow-up was 37 months. Risk of an EFS event was higher with TDM-1+P (hazard ratio [HR], 2.61 [95% CI, 1.36 to 4.98]) with more locoregional progression events before surgery (15 [6.7%] v 0). Risk of an IDFS event after surgery was similar between arms (HR, 1.11 [95% CI, 0.52 to 2.40]). Pathologic complete response was associated with a reduced risk of an IDFS event (HR, 0.24 [95% CI, 0.09 to 0.60]) regardless of treatment arm. Overall, grade 3 or greater AEs (31.8% v 67.7%) were less common with T-DM1+P. During adjuvant treatment, grade 3 or greater AEs (24.5% v 9.9%) and AEs leading to treatment discontinuation (18.4% v 3.8%) were more common with T-DM1+P. Patient-reported outcomes favored T-DM1+P during neoadjuvant treatment and were similar to trastuzumab plus pertuzumab during adjuvant treatment. CONCLUSION: Compared with TCH+P, T-DM1+P resulted in a higher risk of an EFS event owing to locoregional progression events before surgery, a similar risk of an IDFS event, fewer grade 3 or greater AEs during neoadjuvant treatment, and more AEs leading to treatment discontinuation during adjuvant treatment.
引用
- Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019. PMID: 31157583. doi:10.1200/JCO.19.00882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。